FDA is evaluating clinical trial data that may suggest that patients taking Stalevo, a Parkinson's disease medication, may be at an increased risk for developing prostate cancer. In this trial, ...
Carbidopa 31.25mg, levodopa 125mg, entacapone 200mg; tabs. Swallow whole; max one tablet per dosing interval. Previously on carbidopa/levodopa and entacapone: substitute on a mg/mg basis. Stalevo 50, ...
Carbidopa 18.75mg, levodopa 75mg, entacapone 200mg; tabs. Swallow whole; max one tablet per dosing interval. Previously on carbidopa/levodopa and entacapone: substitute on a mg/mg basis. Stalevo 50, ...
August 20, 2010 — The US Food and Drug Administration (FDA) announced today that it is reviewing clinical trial data that suggest patients with Parkinson's disease (PD) taking combined ...
[08-20-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that suggest patients taking Stalevo (a combination of carbidopa/levodopa and entacapone) may be at an ...
ESPOO, Finland, Jan. 24, 2008-Orion Corporation has been informed by its marketing partner Novartis about the positive outcome of FIRST-STEP, a Phase 3 clinical study conducted by Novartis in 423 ...
The Food and Drug Administration on Friday cautioned that it is investigating the possibility that the combination Parkinson’s drug Stalevo may increase the risk of heart attack, stroke and death in ...
Orion Corporation and Novartis Pharma AG have agreed that Novartis will return the sales and distribution rights in certain European countries for Parkinson`s disease drug Stalevo® to Orion. The sales ...
October 31, 2008 — The US Food and Drug Administration (FDA) has approved lacosamide as add-on therapy for adults with partial-onset seizures, and 2 new dosage strengths of a compound combining ...
US regulators have notified healthcare professionals of an ongoing safety review of Novartis and Orion’s Parkinson’s disease drug Stalevo, on fears that the drug may be linked to cardiovascular risks.
Referring to the release published by the US Food and Drug Administration (FDA) on 31 March 2010 concerning the safety review of Orion's drug Stalevo (levodopa ...
Espoo, Finland, Nov 14, 2007 - (Hugin via ABN Newswire) - Company states the realisation of generic competition is neither certain nor imminent Orion Corporation has filed a patent infringement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results